Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") has reviewed the development strategy for the Marketing Authorization Applications (MAAs) for its investigational compounds, alogliptin and alogliptin/ACTOS (generic name: pioglitazone HCl), in Europe, and accordingly, has initiated an additional long-term clinical study for alogliptin.
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has entered into a definitive agreement to form a new Joint Venture with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Shenzhen Neptunus) focused on developing and manufacturing influenza vaccines for the Chinese market.
Sanofi-aventis to strengthen Insulin Production Capacities
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that Sanofi-Aventis Deutschland GmbH has purchased from Pfizer the Diabel manufacturing plant in Frankfurt-Höchst, Germany, one of the largest state-of-the-art insulin manufacturing plants in the world.
Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust
- Details
- Category: Novartis
Novartis announced that the Novartis Vaccines Institute for Global Health (NVGH) has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for Typhoid fever, a disease that affects more than 21 million people worldwide every year.
Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) jointly have announced headline results from the first three clinical trials in the phase III development programme with Lu AA21004 in major depressive disorder (MDD). Previously reported clinical phase II data showed equal efficacy with the 5 and 10 mg doses.
World Health Organization grants Global Prequalification to GSK's Rotarix⢠vaccine
- Details
- Category: GlaxoSmithKline
The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline Biologicals' vaccine against rotavirus, Rotarix™.Additionally, the WHO's Strategic Advisory Group of Experts (SAGE) also recommended that rotavirus vaccination be included in all national immunisation programmes.
New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
More Pharma News ...
- AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix
- FDA approves Reclast® to prevent osteoporosis in postmenopausal women
- Schering-Plough Announces European Filing of SYCREST(R) (asenapine)
- New study first ever to directly compare once-daily Levemir® with another basal insulin analogue
- Genzyme Completes Transaction with Bayer HealthCare
- AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer